Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib
Enrollment for the PROSERA study officially closed on June 11. The study is a double-blind, placebo-controlled clinical trial designed to assess seralutinib's efficacy when administered in addition to standard PAH therapy. Patients in the trial are randomly assigned in a 1:1 ratio to either the seralutinib or placebo groups and will receive blinded treatment for up to 48 weeks.
A hand holding up a glass vial containing a biopharmaceutical therapy.
The primary endpoint for the PROSERA Study is the change in six-minute walk distance (6MWD) from baseline compared to placebo at Week 24. Key secondary endpoints include time to clinical worsening, as compared to placebo, up to Week 48, along with other secondary and exploratory endpoints, and an evaluation of safety and tolerability. Topline results from the Phase 3 PROSERA Study are anticipated in February 2026.
Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company that develops and commercializes seralutinib for the treatment of pulmonary arterial hypertension/PAH in the US. Chiesi Farmaceutici is a pharmaceutical firm that researches, develops, produces, and markets medicines for respiratory, neonatology, rare diseases, and special care therapeutic areas.
While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the .
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Why Nano Dimension Stock Triumphed on Thursday
Key Points Investors liked that the company's financial reporting will be more aligned with that of most publicly traded companies in the U.S. It has adopted the GAAP accounting standard. 10 stocks we like better than Nano Dimension › Usually, with publicly traded companies, a change in accounting regime doesn't have much of an effect on investor sentiment. That wasn't quite the case Thursday with additive manufacturing specialist Nano Dimension (NASDAQ: NNDM), which saw its share price bump almost 3% higher on news of such a shift. That rise contrasted rather well with the slight (0.4%) decrease of the S&P 500 index. Four important new initials The change is from International Financial Reporting Standards (IFRS) frequently used by companies overseas, to the generally accepted accounting principles (GAAP) heavily favored in the U.S. This move is pleasing to the many U.S. investors who either hold or track the stock, as from now the company's financials will be in line with some of the top businesses in this country. For anyone who isn't an accountant, IFRS and GAAP statements look fairly similar, with few significant disparities. As part of its shift, Nano Dimension published its 2024 annual results under GAAP standards. Not surprisingly, they matched the IFRS figures for the most part -- revenue was the same, at under $57.8 million, as were balance sheet items such as cash and cash equivalents, and inventory. Still deep in the red There were several differences worth noting, though, mainly in the profit and loss statement's bottom line. The company's net loss across 2024 was a touch steeper under the new standard, at just under $99.9 million; the IFRS-compliant deficit was $96.9 million. No line item experienced such a drastic change as to warrant concern, or shift anyone's take on Nano Dimension's performance. So ultimately, the accounting move was taken as a positive by market players. Should you invest $1,000 in Nano Dimension right now? Before you buy stock in Nano Dimension, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nano Dimension wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,624!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,117!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nano Dimension Stock Triumphed on Thursday was originally published by The Motley Fool Sign in to access your portfolio
Business Wire
36 minutes ago
- Business Wire
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public. So What: If you purchased Telix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, which was 'seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates.' On this news, Telix's American Depositary Receipt ('ADR') price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
an hour ago
- Yahoo
Why Canadian Solar Plummeted Today
Key Points Canadian Solar's second-quarter results came in below expectations, with a tepid outlook. President Trump also said his administration would not approve any more solar projects, calling wind and solar "the scam of the century." The entire solar sector was down on the news, but Canadian Solar especially so. 10 stocks we like better than Canadian Solar › Shares of solar module manufacturer and project developer Canadian Solar (NASDAQ: CSIQ) plunged 18% on Thursday as of 2:05 p.m. ET. Canadian Solar faced a double whammy today. Not only did President Donald Trump make comments on social media that eviscerated the entire solar sector, but Canadian Solar also delivered an underwhelming Q2 earnings report. A miss on both lines and uncertainty about the future In the second quarter, Canadian Solar's revenue grew just 3.9%, with an adjusted (non-GAAP) net loss per share of $0.53. While both figures improved relative to the prior-year quarter, they handily missed analyst estimates. The company did point out its solar module shipments came in at the higher end of the guidance range, and gross margin exceeded the high end. However, that gross margin was helped out by the one-time recognition of an unrealized gain for sales-type leasing, and module volumes were driven by a surge of orders in China. In other words, these figures were higher than normal, with the gross margin improvement based largely on accounting. CEO Shawn Qu also forecast a slowdown, saying, "Following the surge in installations in China during the first half, we expect demand to normalize as the market adjusts to a new paradigm." To that end, management forecast just $1.4 billion in revenue at the midpoint for the third quarter, down from $1.73 billion in the second quarter, with gross margin normalizing down to 15% at the midpoint. Speaking of Qu's mention of a "new paradigm," President Donald Trump cast a pall over the entire solar sector today with a post on his social media platform, Truth Social, writing: Any State that has built and relied on WINDMILLS and SOLAR for power are seeing RECORD BREAKING INCREASES IN ELECTRICITY AND ENERGY COSTS. THE SCAM OF THE CENTURY! We will not approve wind or farmer destroying Solar. The days of stupidity are over in the USA!!! MAGA It wasn't clear exactly what prompted Trump's threat to not approve any more solar projects. Electricity prices have increased over the past year, but experts attribute that to the rise of energy-hungry artificial intelligence (AI) data centers and onshore manufacturing, initiatives that Trump has supported, and which have lifted prices in states with both lots of renewables and little renewables alike. Solar stocks under the microscope Solar stocks have continued to largely struggle this year, seemingly validating the fears ever since last year's election. Clearly, the administration is hostile to solar and wind projects, so the industry will have to figure out how to navigate this overhang. On the bright-ish side, only 23% of Canadian Solar's development pipeline comes from North America. So while more restrictions on U.S. solar projects would be a headwind, the company may be able to continue diversifying away from the U.S. for its growth. Should you buy stock in Canadian Solar right now? Before you buy stock in Canadian Solar, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Canadian Solar wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,624!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,117!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Billy Duberstein and/or his clients no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Canadian Solar Plummeted Today was originally published by The Motley Fool Sign in to access your portfolio
